Truist Financial Corp Chemo Centryx, Inc. Transaction History

Truist Financial Corp

$62.9 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 Apr 22, 2022	SELL	$22.22 - $39.12 $1.76 Million - $3.09 Million	-79,076 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $28,580 - $62,977	-1,555 Reduced 1.93%	79,076 $2.88 Million
Q3 2021 Nov 05, 2021	SELL	$13.18 - $19.83 $184,177 - $277,104	-13,974 Reduced 14.77%	80,631 $1.38 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $323,931 - $1.72 Million	33,778 Added 55.53%	94,605 $1.27 Million
Q4 2020 Nov 19, 2021	SELL	$47.25 - $65.16 $168,540 - $232,425	-3,567 Reduced 5.54%	60,827 $3.77 Million
Q4 2020 Feb 18, 2021	BUY	$47.25 - $65.16 $159,374 - $219,784	3,373 Added 5.53%	64,394 $3.99 Million
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $8,991 - $11,967	194 Added 0.32%	61,021 $3.34 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $414,231 - $2.41 Million	60,827 New	60,827 $2.41 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.